Hint mode is switched on Switch off
For swift navigation between sections

Organization: Vertex Pharmaceutical
LEI 54930015RAQRRZ5ZGJ91, SWIFT VRTXUS33XXX

Organization name
Vertex Pharmaceuticals Incorporated
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Bond debt
-

explore the most comprehensive database

800 000

bonds globally

Over 400

pricing sources

80 000

stocks

9 000

ETF

track your portfolio in the most efficient way
Bond Search
Watchlist
Excel ADD-IN
Get access
×

— Are you looking for the complete & verified bond data?

— We have everything you need:

full data on over 700 000 bonds, stocks & ETFs; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available anywhere via Website, Excel Add-in and Mobile app.

Register
×

Why

You will have detailed descriptive & pricing data for 650K bonds, 76K stocks, 8K ETFs
Get full access to the platform from any device & via Cbonds app
Enhance your portfolio management with Cbonds Excel Add-in
Build yield maps, make chart comparison within a click
Don't wait any longer — start using Cbonds today! Register

Latest data on

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Vertex Pharmaceuticals Incorporated (Vertex) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases. The Company’s two products are INCIVEK (telaprevir), which is approved for the treatment of patients with genotype 1 hepatitis C virus (HCV), infection, and KALYDECO (ivacaftor), which is approved in the United States for the treatment of patients six years of age and older with cystic fibrosis (CF), who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR), gene. The Company has ongoing clinical programs involving drug candidates intended for the treatment of HCV infection, CF, rheumatoid arthritis, influenza and epilepsy. / upd. 08. 2012

Awards

News

05/02/2024 Vertex Pharmaceutical: Results Of Operations And Financial Condition, Financial Statements And Exhibits
08/12/2023 Vertex Pharmaceutical: Other Events
05/12/2023 Vertex Pharmaceutical: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers
06/11/2023 Vertex Pharmaceutical: Results Of Operations And Financial Condition, Financial Statements And Exhibits
03/10/2023 Vertex Pharmaceutical: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers
All organization news

Documentation

IFRS/US GAAP reports

2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Bond debt by currency

Show more Hide

Codes

  • LEI
    54930015RAQRRZ5ZGJ91
  • SWIFT
    VRTXUS33XXX
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • CIK
    0000875320
  • EIN
    04-3039129

Credit and ESG Ratings

Macroeconomic Indicators - Vertex Pharmaceutical

Registration is required to get access.